Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design

Gossamer Bio, Inc.

Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.
Warrants exercisable at $2.04/share, immediately exercisable, expire July 24, 2028.
Net proceeds to fund seralutinib development/commercialization and working capital.
Participation from NEA, EcoR1, Armistice, Farallon, Madison Avenue Partners, and others.
Interim TORREY OLE data and PROSERA Phase 3 design disclosed via separate 8-K; conference call July 25.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Gossamer Bio, Inc. entered into Purchase Agreement with purchasers named therein, including certain directors and executive officers of the Company valued at approximately $212.1 million (effective 2023-07-19).

Action: entry
Agreement: equity purchase
Counterparty: purchasers named therein, including certain directors and executive officers of the Company
Value: approximately $212.1 million
Effective: 2023-07-19

Exact text from the filing

On July 19, 2023, Gossamer Bio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein, including certain directors and executive officers of the Company (the “Purchasers”), for the private placement (the “Private Placement”) of 129,869,440 shares

View on SEC.gov

24 material agreements filed in the last 30 days. Browse all material agreements →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.